DUBLIN–(BUSINESS WIRE)–The “HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This HR+/HER2-VE Breast Cancer – Pipeline Insight, 2021 provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HR+/HER2-VE Breast Cancer pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence HR+/HER2-VE Breast Cancer R&D. The therapies under development are focused on novel approaches for HR+/HER2-VE Breast Cancer.
HR+/HER2-VE Breast Cancer Emerging Drugs Chapters
This segment of the HR+/HER2-VE Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
HR+/HER2-VE Breast Cancer Emerging Drugs
AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of development and is being developed by Astrazeneca.
BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers.
It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene’s investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
Major Players working on HR+/HER2-VE Breast Cancer
There are approx. 40+ key companies which are developing the HR+/HER2-VE Breast Cancer. The companies which have their HR+/HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
HR+/HER2-VE Breast Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses HR+/HER2-VE Breast Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HR+/HER2-VE Breast Cancer drugs.
HR+/HER2-VE Breast Cancer Report Insights
- HR+/HER2-VE Breast Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
HR+/HER2-VE Breast Cancer Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
- How many companies are developing HR+/HER2-VE Breast Cancer drugs?
- How many HR+/HER2-VE Breast Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for HR+/HER2-VE Breast Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the HR+/HER2-VE Breast Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for HR+/HER2-VE Breast Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- BeiGene
- H3 Biomedicine
- AstraZeneca
- Olema Pharmaceuticals
- CytomX Therapeutics
- Roche
- G1 Therapeutics
- Sanofi
- Jiangsu HengRui Medicine
Key Products
- BGB-290
- H3B-6545
- AZD9833
- OP-1250
- CX-2009
- RG6171
- Rintodestrant
- Amcenestrant
- SHR6390
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/bapzpx
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900